When it comes to the calendar of months dedicated to raising awareness of illnesses or medical conditions, a few may come to mind. October is for raising awareness of breast cancer, May is for mental ...

Experts discuss the role of multidisciplinary teams, gene expression patterns, rare disease drug designation, and education gaps in managing desmoid tumors, emphasizing the need for comprehensive care ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...

During a recent AJMC Peer Exchange, a panel of experts delved into the clinical characteristics and heterogeneity of desmoid tumors, the importance of a multidisciplinary approach in both ...

In the GRAFITI trial at a median follow-up of 33.7 months, about 30% of patients started some form of active treatment following AS, reported Anne-Rose W. Schut, a PhD candidate at Erasmus Medical ...

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with ...

A phase 3 clinical trial (research study) of a targeted therapy called nirogacestat has found that the drug significantly shrank desmoid tumors in 41% of patients. Desmoid tumors (also known as ...

FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...

Nirogacestat significantly improved PFS compared with placebo among patients with progressing desmoid tumors, according to phase 3 study results presented at ESMO Congress. Perspectives from Andrew S.

Desmoid tumours, also known as desmoid-type fibromatosis, represent a rare yet locally aggressive proliferation of fibroblasts. Despite their benign classification due to the lack of metastatic ...